

MINISTRY OF CHEMICALS AND FERTILISERS

DEMAND NO. 7

Department of Pharmaceuticals*(In ₹ crores)*

	Actual 2020-2021			Budget 2021-2022			Revised 2021-2022			Budget 2022-2023		
	Revenue	Capital	Total	Revenue	Capital	Total	Revenue	Capital	Total	Revenue	Capital	Total
Gross	449.01	7.15	456.16	461.29	9.12	470.41	1758.20	148.12	1906.32	2238.85	5.30	2244.15
Recoveries	-0.15	...	-0.15
Receipts	-1083.21	...	-1083.21
Net	448.86	7.15	456.01	461.29	9.12	470.41	674.99	148.12	823.11	2238.85	5.30	2244.15
A. The Budget allocations, net of recoveries and receipts, are given below:												
CENTRE'S EXPENDITURE												
Establishment Expenditure of the Centre												
1. Secretariat	14.40	...	14.40	16.73	...	16.73	15.98	...	15.98	18.56	...	18.56
2. National Pharmaceutical Pricing Authority (NPPA)	12.74	...	12.74	14.80	...	14.80	14.01	...	14.01	17.79	...	17.79
Total-Establishment Expenditure of the Centre	27.14	...	27.14	31.53	...	31.53	29.99	...	29.99	36.35	...	36.35
Central Sector Schemes/Projects												
3. National Institutes of Pharmaceutical Education and Research (NIPERs)	306.27	...	306.27	215.34	...	215.34	350.00	...	350.00	350.00	...	350.00
4. Jan Aushadhi Scheme	65.00	...	65.00	65.00	...	65.00	68.50	...	68.50	72.50	...	72.50
5. Development of Pharmaceutical Industry	20.45	...	20.45	124.42	...	124.42	0.02	...	0.02
6. Consumer Awareness Publicity and Price Monitoring	2.60	...	2.60	6.00	...	6.00	4.50	...	4.50	6.00	...	6.00
Development of Pharmaceutical Industry												
7. <i>Development of Pharmaceutical Industry</i>												
7.01 Pharmaceutical Promotion & Development Scheme(PPDS)	2.00	...	2.00	2.00	...	2.00
7.02 Assistance to Pharmaceutical Industry for Common Facilities(API-CF)/Cluster Development	15.61	...	15.61	36.00	...	36.00
7.03 Pharmaceuticals Technology Upgradation Assistance Scheme(PTUAS)	0.01	...	0.01	62.00	...	62.00
<i>Total- Development of Pharmaceutical Industry</i>	<i>17.62</i>	...	<i>17.62</i>	<i>100.00</i>	...	<i>100.00</i>
Production Linked Incentive Schemes												
8. <i>Production Linked Incentive Schemes</i>												
8.01 Promotion of Bulk Drug Parks	36.24	...	36.24	900.00	...	900.00
8.02 Production Linked Incentive(PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials(KSMs)/Drug	2.79	...	2.79	390.00	...	390.00

(In ₹ crores)

	Actual 2020-2021			Budget 2021-2022			Revised 2021-2022			Budget 2022-2023		
	Revenue	Capital	Total	Revenue	Capital	Total	Revenue	Capital	Total	Revenue	Capital	Total
Intermediates(DIs) and Active Pharmaceutical Ingredients(APIs) in India												
8.03 Promotion of Medical Device Parks	137.02	...	137.02	120.00	...	120.00
8.04 Production Linked Incentive (PLI) Scheme for Domestic Manufacturing of Medical Devices	3.31	...	3.31	216.00	...	216.00
8.05 Production Linked Incentive Scheme for Pharmaceuticals	3.00	...	3.00	3.00	...	3.00
<i>Total- Production Linked Incentive Schemes</i>	182.36	...	182.36	1629.00	...	1629.00
Total-Central Sector Schemes/Projects	394.32	...	394.32	410.76	...	410.76	623.00	...	623.00	2157.50	...	2157.50
Other Central Sector Expenditure												
Autonomous Bodies												
9. National Institute of Pharmaceutical Education and Research(NIPERs)	27.55	...	27.55	19.00	...	19.00	22.00	...	22.00	45.00	...	45.00
Public Sector Undertakings												
10. Assistance to PSUs	...	7.15	7.15	...	9.12	9.12	...	148.12	148.12	...	5.30	5.30
11. <i>Write Off/Waiver of losses in respect of Pharmaceuticals PSUs</i>												
11.01 India Drugs and Pharmaceuticals Limited(IDPL)	889.50	...	889.50
	-889.50	...	-889.50
<i>Net</i>
11.02 Bengal Chemicals & Pharmaceuticals Limited(BCPL)	193.71	...	193.71
	-193.71	...	-193.71
<i>Net</i>
<i>Net</i>
Total-Public Sector Undertakings	...	7.15	7.15	...	9.12	9.12	...	148.12	148.12	...	5.30	5.30
Total-Other Central Sector Expenditure	27.55	7.15	34.70	19.00	9.12	28.12	22.00	148.12	170.12	45.00	5.30	50.30
TRANSFERS TO STATES/UTs												
Other Grants/Loans/Transfers												
12. Recovery	-0.15	...	-0.15
Grand Total	448.86	7.15	456.01	461.29	9.12	470.41	674.99	148.12	823.11	2238.85	5.30	2244.15
B. Developmental Heads												
Economic Services												
1. Industries	434.46	...	434.46	406.85	...	406.85	596.70	...	596.70	2178.09	...	2178.09

(In ₹ crores)

	Actual 2020-2021			Budget 2021-2022			Revised 2021-2022			Budget 2022-2023		
	Revenue	Capital	Total	Revenue	Capital	Total	Revenue	Capital	Total	Revenue	Capital	Total
2. Secretariat-Economic Services	14.40	...	14.40	16.73	...	16.73	15.98	...	15.98	18.56	...	18.56
3. Loans for Chemical and Pharmaceutical Industries	...	7.15	7.15	...	9.12	9.12	...	148.12	148.12	...	5.30	5.30
Total-Economic Services	448.86	7.15	456.01	423.58	9.12	432.70	612.68	148.12	760.80	2196.65	5.30	2201.95
Others												
4. North Eastern Areas	37.71	...	37.71	62.31	...	62.31	42.20	...	42.20
Total-Others	37.71	...	37.71	62.31	...	62.31	42.20	...	42.20
Grand Total	448.86	7.15	456.01	461.29	9.12	470.41	674.99	148.12	823.11	2238.85	5.30	2244.15
	Budget Support	IEBR	Total	Budget Support	IEBR	Total	Budget Support	IEBR	Total	Budget Support	IEBR	Total
C. Investment in Public Enterprises												
1. Karnataka Antibiotics and Pharmaceuticals Ltd	...	23.18	23.18	...	33.75	33.75	...	30.00	30.00	...	33.00	33.00
2. Indian Drugs and Pharmaceuticals Ltd	2.23	...	2.23	2.00	...	2.00	4.00	...	4.00
3. Hindustan Antibiotics Ltd	2.52	...	2.52	122.09	...	122.09	1.26	...	1.26
4. Bengal Chemicals and Pharmaceuticals Ltd	0.01	...	0.01	0.01	...	0.01
5. Bengal Immunity Ltd	0.01	...	0.01	0.01	...	0.01
6. Rajasthan Drugs and Pharmaceuticals Ltd	2.40	...	2.40	24.00	...	24.00	0.01	...	0.01
7. Smith Stanistreet Pharmaceuticals Ltd	0.01	...	0.01	0.01	...	0.01
Total	7.15	23.18	30.33	...	33.75	33.75	148.12	30.00	178.12	5.30	33.00	38.30

1. **Secretariat:** The provision is for the Salary and Establishment Expenditure of Department of Pharmaceuticals.

2. **National Pharmaceutical Pricing Authority (NPPA):** The provision is for the Secretariat and Establishment Expenditure of NPPA,

3. **National Institutes of Pharmaceutical Education and Research (NIPERs):** The provision is made for 7 NIPERs i.e. Mohali, Ahmedabad, Guwahati, Hajipur, Hyderabad, Kolkata and Rae Bareli for incurring establishment and other expenditure.

4. **Jan Aushadhi Scheme:** Under the Jan Aushadhi Scheme for effective implementation of Pradhan Mantri Bhartiya Janaushadhi Pariyojana(PMBJP).

6. **Consumer Awareness Publicity and Price Monitoring:** The provision is for Consumer Awareness, Publicity and providing support to State resource units.

7.01. **Pharmaceutical Promotion & Development Scheme(PPDS):** The provision for promotion, development and export promotion in Pharmaceuticals sector by extending financial support for conduct of seminars, conferences, exhibitions, mounting delegation to and from India for promotion of exports as well as investments, conduction studies/ consultancies for facilitating growth, export as well as critical issues affecting Pharma Sector.

7.02. **Assistance to Pharmaceutical Industry for Common Facilities(API-CF)/Cluster Development:** The Scheme would be implemented in a Public Private Partnership (PPP) mode through one time grant-in-aid to be released in various phases for creation of identified infrastructure and common facilities to a Special Purpose Vehicles (SPVs) set up for the purpose.

7.03. **Pharmaceuticals Technology Upgradation Assistance Scheme(PTUAS):** The sub-scheme is aimed at providing interest subvention to the eligible Small and Medium Scale Pharma Units having GMP compliant manufacturing facilities both for Bulk Drugs and Pharmaceuticals formulations. The eligible units intending to upgrade their manufacturing infrastructure to attain WHO-GMP norms, have to secure loan from any Financial Institution for upgrading their infrastructure and technology.

8.01. **Promotion of Bulk Drug Parks:** To promote setting up of bulk drug parks in the country for providing easy access to world class Common Infrastructure Facilities (CIF) to bulk drug units located in the park in order to significantly bring down the manufacturing cost of bulk drugs and thereby make India self-reliant in bulk drugs by increasing the competitiveness of the domestic bulk drug industry.

8.02. **Production Linked Incentive(PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials(KSMs)/Drug Intermediates(DIs) and Active Pharmaceutical Ingredients(APIs) in India:** The objective of the scheme is to attain self-reliance and reduce import dependence in critical KSMs/DIs/APIs. Under the scheme, financial incentives shall be given based on committed investment and sales made by selected applicant for the eligible products.

8.03. **Promotion of Medical Device Parks:** Creation of world class infrastructure facilities in order to make Indian medical device industry a global leader. Easy access to standard testing and infrastructure facilities through creation of world class Common Infrastructure Facilities for increased competitiveness will result in significant reduction of the cost of production of medical devices leading to better availability and affordability of medical devices in the domestic market.

8.04. **Production Linked Incentive (PLI) Scheme for Domestic Manufacturing of Medical Devices:** The scheme proposes a financial incentive to boost domestic manufacturing and attract large investment in the Medical Device Sector.

8.05. **Production Linked Incentive Scheme for Pharmaceuticals:** The objective of the scheme is to enhance India manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high value goods in the pharmaceutical sector.

9. **National Institute of Pharmaceutical Education and Research(NIPERs):** The provision has been made for salary of employees of 7 NIPERs i.e. Mohali, Ahmedabad, Guwahati, Hajipur, Hyderabad, Kolkata and Rae Bareli.

10. **Assistance to PSUs:** These are provisions under loan kept for the 6 Pharmaceuticals Public Sector Undertakings(PSUs).